What PRESTIGE BIOLOGICS CO LTD does

PRESTIGE BIOLOGICS CO LTD is a South Korea-based, KOSDAQ-listed (ticker 334970) contract development and manufacturing organization (CDMO) founded in 2015 as part of the Prestige Biopharma Group, offering integrated biologics services — contract development (CDO), contract manufacturing (CMO), contract packaging (CPO), and analytical testing — for antibody drug substances and drug products from cell-line development through commercial supply. The company operates four purpose-built cGMP facilities on two campuses in the Osong Life Science Bio-cluster near Cheongju, with a total installed bioreactor capacity of approximately 154,000 L across 77 × 2,000 L SUB units, supported by EU GMP, Korean MFDS GMP, WHO GDP, and ISO 9001/14001/45001 certifications.

The technical core is the patented ALITA Smart BioFactory™ platform, a hybrid architecture pairing Single-Use Bioreactors upstream with Stainless Steel downstream, augmented by proprietary systems (Aseptic Connection System, In-Situ Automatic Filter, PLC-based component buffer preparation, Non-Protein A antibody purification, glycan-content-controlled cell culture, and an AI-based cell culture condition optimization engine patented in April 2025). The company performs on equipment from Cytiva and Thermo Fisher Scientific, with Veeva, SAP ERP, and Emerson as the digital systems stack.

The business operates as a fee-for-service enterprise CDMO with custom multi-year project quotes, including a 4-week CDMO quotation program and a 3-week CPO quotation program. Go-to-market is enterprise field sales supplemented by Seoul-based business development, presence at BIO USA and JP Morgan Healthcare Conference, and a strategic referral network anchored by Charles River Laboratories (MOU signed June 2026). Revenue is concentrated in clinical and commercial biosimilar supply, with the parent group (Prestige Biopharma Group) historically the largest single customer and external global pharma customers — including Teva for European supply of Tuznue (HD201) and Intas/Accord for HD204 — now driving the bulk of the disclosed ~KRW 650 billion cumulative order backlog as of March 2026.

Name

PRESTIGE BIOLOGICS CO LTD

Legal name

Prestige Biologics Co.,Ltd.

Website

https://prestigebiologics.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

PRESTIGE BIOLOGICS CO LTD is a KOSDAQ-listed South Korean biopharmaceutical CDMO providing integrated contract development, manufacturing, packaging, and analytical testing services for antibody drug substances and products across four cGMP plants totaling ~154,000 L of bioreactor capacity, serving global pharma and biosimilar developers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Biologics contract manufacturing
• CDMO development services
• Antibody drug substance
• Aseptic fill finish
• Biopharmaceutical process development

Headquarters

HQ city

Cheongju

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Contract Manufacturing (CMO): Revenue from contract manufacturing of biopharmaceutical drug substance (DS) and drug product (DP) across four GMP facilities. Includes clinical and commercial scale manufacturing. Revenue recognition follows production completion and quality release, with a structural lag between production activity and accounting recognition due to CDMO industry characteristics.
2. Contract Development Organization (CDO): Fees from process development services including cell line development, upstream/downstream process development, analytical method development, and IND filing support. Typically recognized as part of integrated CDMO project contracts.
3. Contract Packaging Organization (CPO): Revenue from secondary packaging services for clinical trial medicinal products including labeling, serialization, de-labeling, re-labeling, storage, and cold chain distribution services.
4. Analytical Testing Services: Fees for quality and regulatory-driven analytical services including physicochemical characterization, biological assays, stability testing, impurity analysis, and release testing aligned with ICH guidelines.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Prestige Biologics is an integrated biologics CDMO providing end-to-end contract development, manufacturing, packaging, and analytical testing services for biopharmaceutical drug substance and drug product. Operating four cGMP plants (P1-P4) at the Osong Bio-cluster in Cheongju, South Korea with a combined 154,000L bioreactor capacity, the company serves global pharma, biosimilar developers and innovative drug developers from cell line development and IND filing support through commercial-scale GMP manufacturing and secondary packaging. The proprietary ALITA Smart BioFactory™ hybrid platform combines Single-Use Bioreactor upstream with Stainless Steel downstream, patented Aseptic Connection System (ACS), Non-Protein A purification, and AI-based cell culture optimization.

Product overview

PRESTIGE BIOLOGICS CO LTD operates as an integrated biopharmaceutical CDMO (Contract Development and Manufacturing Organization) offering end-to-end services from development through commercial manufacturing. The company's portfolio centers on four core service offerings: CDO (Contract Development Organization) for process development, CMO (Contract Manufacturing Organization) for GMP manufacturing, CPO (Contract Packaging Organization) for secondary packaging, and Analytical Testing Services. These are unified by the proprietary ALITA Smart BioFactory™ technology platform, which enables hybrid manufacturing combining Single-use Bioreactors with Stainless Steel downstream processing. The company operates four manufacturing plants (P1, P2, P3, P4) across two campuses in Osong, Korea, with a total production capacity of 154,000L. Additional proprietary technologies include the Non-Protein A Purification Process for cost-effective antibody manufacturing. The company supports customers through quotation programs (4-week CDMO, 3-week CPO) and operates under an Open-door Policy for transparent customer collaboration.

Differentiator

Problem solved

Functional benefit

Products and services

• CDO (Contract Development Organization) Comprehensive process development services including cell line development, upstream/downstream process optimization, analytical method development, and IND filing support from early nonclinical stages through commercial manufacturing. Specialized teams optimize USP and DSP processes to maximize yield and purity of biopharmaceuticals while enabling stable scale-up.
• CMO (Contract Manufacturing Organization) GMP-compliant manufacturing services from clinical supply through commercial scale production, utilizing Full Single-Use and hybrid production capabilities across four facilities with 154,000L total bioreactor capacity. Covers Phase I through commercial production with stable supply and complete regulatory compliance and quality assurance.
• CPO (Contract Packaging Organization) Secondary packaging services for clinical trial medicinal products including labeling, serialization, de-labeling, re-labeling, and temperature-controlled storage and distribution under GMP and GDP certified facilities. Project-specific SOPs are established per customer requirements under EU and international GMP standards.
• Analytical Testing Services Comprehensive analytical services including physicochemical characterization, biological assays, stability testing, impurity analysis, and regulatory submission support aligned with ICH guidelines for IND, BLA, and commercial launch. Advanced laboratories conduct testing per ICH guidelines to support global submissions.
• ALITA Smart BioFactory™ Hybrid Manufacturing Platform Proprietary patented hybrid manufacturing platform combining Single-Use Bioreactors upstream with Stainless Steel downstream processing, applied at Plant 4 (P4 ADVENTURE, 32,000L). Includes predictive engineering models and smart operational systems, plus patent-protected Aseptic Connection System (ACS), In-Situ Automatic Filter, and PLC-based buffer preparation. Enables flexible, high-volume biopharmaceutical manufacturing with minimized cross-contamination risk and reduced consumable/operating costs.
• One-Stop Solution (Integrated CDMO Services) Fully integrated CDMO service bundle combining development, manufacturing, testing, and packaging into a single end-to-end engagement. Simplifies supply chain, shortens development timelines, and ensures seamless technology transfer for customers seeking a single CDMO partner across the development-to-commercial lifecycle.
• Non-Protein A Antibody Purification Process Proprietary antibody purification platform that eliminates Protein A resin usage, reducing purification costs and improving production efficiency while maintaining antibody quality through various separation and purification techniques. Enables greater process flexibility and lower cost of goods.

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• Charles River Laboratories InternationalflagshipStrategic or Co-development Partner · 22 June 2026Strategic MOU signed at BIO USA 2026 (June 2026) for collaboration on biopharmaceutical development, testing, analysis, and manufacturing. Charles River refers GMP manufacturing clients to Prestige Biologics while Prestige Biologics refers early-stage discovery and preclinical clients to Charles River. Key cooperation areas: analytical method development, QC and batch release testing, biosafety/viral safety evaluation, cell line characterization, GLP toxicology, PK/PD research. Charles River generated ~USD 4.02 billion revenue in 2025.
• Teva Pharmaceutical IndustriescoreChannel Partner/ Reseller/ Distributor · 1 September 2024Exclusive licensing and supply agreement for Tuznue (HD201, trastuzumab biosimilar) covering 31 European countries. Teva placed first commercial order of EUR 743,110 in October 2025. Teva is a global pharmaceutical company with ~USD 23 trillion revenue (approximately USD 23 billion), making it a major commercial partner for European market access.
• Intas Pharmaceuticals / Accord HealthcarecoreChannel Partner/ Reseller/ Distributor · 1 January 2024Global supply agreement for HD204 (bevacizumab biosimilar, brand name Vaspoda). Accord Healthcare (Intas subsidiary) handles US and European regulatory filings for HD204 commercialization. Planned regulatory submissions to major authorities in H2 2026.
• Chungcheongbuk-do Free Economic Zone AuthorityminorOthersFirst regional partnership established in November 2016 with the signing of an MOU with Chungcheongbuk-do Free Economic Zone Authority, marking the company's early-stage regional collaboration.

Scale indicators8 records

Recent moves9 records

Expansion highlights8 records

Direct peers

• Samsung Biologics: Korean-based global biologics CDMO and the largest in Asia, operating multi-hundred-thousand liter capacity. Directly comparable to Prestige Biologics as a domestic Korean CDMO competitor targeting global pharma clients for biologics contract manufacturing.
• SK Bioscience: Korean CDMO with biologics manufacturing capabilities serving global vaccine and biopharmaceutical clients. Direct Korean peer competing for similar contract manufacturing projects and FDA/EMA-certified production work.
• AGC Biologics: Global biologics CDMO with mammalian cell culture manufacturing capabilities across US, Europe, and Asia. Comparable as a mid-to-large scale CDMO offering similar mAb/biosimilar manufacturing services with global regulatory certifications.
• Binex: Korean biologics CDMO offering cell culture-based contract manufacturing services. Comparable as a smaller Korean CDMO competitor targeting similar biosimilar and biopharmaceutical contract manufacturing opportunities.

Regional players

• Celltrion: Korean biopharmaceutical company with vertically integrated biosimilar manufacturing operations. Comparable as Korean biosimilar developer/manufacturer, though Celltrion primarily manufactures for its own products rather than third-party CDMO services.

Broad incumbents

• WuXi Biologics: Global biologics CDMO with the largest capacity footprint worldwide, offering end-to-end development and manufacturing. Comparable as a direct competitor in biologics CDMO with overlapping customer base of global pharma and biotech clients seeking large-scale manufacturing.
• Lonza Group: Swiss global CDMO leader with extensive biologics manufacturing capacity across multiple continents. Comparable as a top-tier global biologics CDMO competing for the same large pharma and biotech manufacturing contracts Prestige targets.
• Catalent: Global CDMO providing biologics manufacturing, fill-finish, and analytical services. Comparable as a multi-modality CDMO competing for biologics manufacturing projects, particularly for fill-finish and packaging services similar to Prestige's CPO offering.
• Thermo Fisher Scientific (CDMO division): Global life sciences company with a major CDMO business (Patheon) providing biologics manufacturing services. Comparable as a strategic equipment partner and broader CDMO competitor for large pharma contract manufacturing.

Others

• Charles River Laboratories: Global CRO/CDMO partner that recently signed an MOU with Prestige Biologics. While not a direct competitor, Charles River's discovery/preclinical capabilities complement Prestige's GMP manufacturing, making them an adjacent ecosystem partner for biopharma development services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Customer concentration

• YouTubeyoutube.com/channel/UCfY6Qyj4CW7htR-JG9aDB8g
• LinkedInlinkedin.com/company/prestige-biologics-co-ltd
• Xx.com/P_Biologics
• Facebookfacebook.com/Prestige-Biologics-Co-Ltd-104168354881348

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRESTIGE BIOLOGICS CO LTD